Cargando…

In vivo imaging xenograft models for the evaluation of anti‐brain tumor efficacy of targeted drugs

Molecular‐targeted drugs are generally effective against tumors containing driver oncogenes, such as EGFR,ALK, and NTRK1. However, patients harboring these oncogenes frequently experience a progression of brain metastases during treatment. Here, we present an in vivo imaging model for brain tumors u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kita, Kenji, Arai, Sachiko, Nishiyama, Akihiro, Taniguchi, Hirokazu, Fukuda, Koji, Wang, Rong, Yamada, Tadaaki, Takeuchi, Shinji, Tange, Shoichiro, Tajima, Atsushi, Nakada, Mitsutoshi, Yasumoto, Kazuo, Motoo, Yoshiharu, Murakami, Takashi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727243/ https://www.ncbi.nlm.nih.gov/pubmed/29125233 http://dx.doi.org/10.1002/cam4.1255

Ejemplares similares

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
por: Taniguchi, Hirokazu, et al.
Publicado: (2016)

Impact of MET inhibition on small‐cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway
por: Taniguchi, Hirokazu, et al.
Publicado: (2017)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
por: Kita, Kenji, et al.
Publicado: (2019)

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET
por: Arai, Sachiko, et al.
Publicado: (2017)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
por: Yanagimura, Naohiro, et al.
Publicado: (2022)

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line
por: Nanjo, Shigeki, et al.
Publicado: (2015)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation
por: Takeuchi, Shinji, et al.
Publicado: (2017)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review
por: Nishiyama, Akihiro, et al.
Publicado: (2021)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF
por: Ishikawa, Daisuke, et al.
Publicado: (2013)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
por: Peng, Shunli, et al.
Publicado: (2019)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study
por: Kobayashi, Takashi, et al.
Publicado: (2023)

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018)

Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion
por: Sakai, Katsuya, et al.
Publicado: (2020)

Use of Kampo Diagnosis in Randomized Controlled Trials of Kampo Products in Japan: A Systematic Review
por: Motoo, Yoshiharu, et al.
Publicado: (2014)

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

A Basic Study of Photodynamic Therapy with Glucose-Conjugated Chlorin e6 Using Mammary Carcinoma Xenografts
por: Osaki, Tomohiro, et al.
Publicado: (2019)

Usability of the evidence-based Japanese integrative medicine (eJIM) information site: analysis with focus group discussion and internet survey on the general population
por: Motoo, Yoshiharu, et al.
Publicado: (2018)

Physician perspectives on traditional, complementary, and integrative medicine and the national evidence-based Japanese integrative medicine information website: A mixed-method study
por: Motoo, Yoshiharu, et al.
Publicado: (2021)

Pharmacists’ perspectives on traditional, complementary, and integrative medicine in Japan with special reference to Kampo medicines: an internet survey with preliminary interviews
por: Motoo, Yoshiharu, et al.
Publicado: (2022)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma
por: MICHISHITA, Masaki, et al.
Publicado: (2015)

Posterior-prefrontal and medial orbitofrontal regions play crucial roles in happiness and sadness recognition
por: Nakajima, Riho, et al.
Publicado: (2022)

COT-28 Questionnaire Survey Regarding Working Condition of the Members Belongs to the Japan Society for Neuro-Oncology (JSNO) by the Gender Equality and Diversity Committee of the JSNO, 2021
por: Fujiamaki, Takamitsu, et al.
Publicado: (2021)

What is the best adjustment of appendicular lean mass for predicting mortality or disability among Japanese community dwellers?
por: Otsuka, Rei, et al.
Publicado: (2018)

Clonality Assay of Hematopoietic Disorders: Significance of the Buccal Epithelium as Non‐hematopoietic Control and of 95% Rejection Limit as a Novel Criterion for Monoclonality
por: Inagaki, Hiroshi, et al.
Publicado: (2001)

Use of Complementary and Alternative Medicine in Japan: A Cross-sectional Internet Survey Using the Japanese Version of the International Complementary and Alternative Medicine Questionnaire
por: Motoo, Yoshiharu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sqetrv60q16dl5hd04cfijmq9d